News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)


1/26/2009 9:57:57 AM

OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in mammalian cell culture, today announced the signing of a full service process development and manufacturing collaboration with Selexys Pharmaceutical Corporation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES